Sapio Sciences Partners with Amazon Web Services to Enhance Drug Discovery through AI
Sapio Sciences, renowned for its science-aware lab informatics platform, has announced a significant development in its collaborative relationship with Amazon Web Services, Inc. (AWS). This collaboration involves the integration of AWS Bedrock within the Sapio Platform, a move aimed at providing advanced generative AI models to scientists and researchers. This integration is housed within the secure AWS environment, which also supports Sapio’s Laboratory Information Management System (LIMS) and Electronic Lab Notebook (ELN).
The collaboration is intended to streamline access to a selection of cutting-edge AI foundational models, including those from AI21 Labs, Anthropic, and Stability AI. Users of the Sapio Platform are set to benefit from innovative tools that incorporate science-aware functionalities, such as natural language interactions with the ELN, AI-powered chatbot integration, automated experiment generation from prompts, and advanced natural language search capabilities.
Kevin Cramer, the founder and CEO of Sapio Sciences, remarked on the integration, highlighting the specific design of science-aware AI to simplify the complexities inherent in scientific research. Cramer noted that the AI systems, now embedded in Sapio's lab informatics platform, empower researchers to efficiently collect, manage, and analyse research data, thus promoting precision in scientific work.
Furthermore, Cramer expressed that the partnership with AWS is pivotal in accelerating research and development processes. By utilising the power of natural language interfaces and AI, the platform is expected to save valuable time for laboratory researchers and expedite the discovery of viable scientific solutions. This advancement is poised to enable researchers to engage more fully with high-impact discoveries, fostering innovation and breakthroughs in various life science research areas.
Ben Schreiner, Head of Innovation for Small and Medium Businesses (SMB) at AWS, added his perspective on the collaboration. He emphasised the critical role that AI can play within the life sciences and drug discovery industries. Schreiner articulated the enthusiasm surrounding the extension of AWS’s long-term relationship with Sapio Sciences, expressing optimism about how Sapio’s customers would leverage this combined technology. The goal is to push forward the discovery of new and novel solutions within some of the most challenging scientific fields today.
Sapio Sciences has relied on AWS as its preferred cloud provider for over a decade. Customers use AWS to securely host Sapio’s configurable lab informatics platform, which features no-code/low-code elements.
Sapio Sciences’ mission is to enhance lives through the acceleration of scientific discovery. Recognising the complexity of science, the company aims to simplify the associated technology. It offers a comprehensive science-aware lab informatics platform that includes cloud-based LIMS, ELN, and Jarvis data solutions. Sapio serves a broad range of clients, from large global enterprises to specialised brands in biopharma, clinical diagnostics, and other scientific domains, including genomic sequencing and bioprocessing.
Whether through its robust and scalable platform or its ability to quickly adapt to unique client needs, Sapio Sciences continues to garner appreciation from its users. As the integration with AWS Bedrock unfolds, all eyes are on how this partnership might catalyse advancements in drug research and discovery.
Source: Noah Wire Services